Posts

Showing posts from August, 2019

Conjunctivitis Market Analysis, Major Competitor and Strategies, Regional Outlook 2019 To 2024 - Materials Post

Image
Conjunctivitis Global Market 2019-2024 covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market. Global Conjunctivitis Market report provides strategists, marketers and senior management with the critical information they need to assess the global Conjunctivitis sector. The market size section gives the Conjunctivitis market revenues, covering both the historic growth of the market and forecasting the future. Access Global Conjunctivitis Market Research Report Details at: at  https://www.pioneerreports.com/report/338966     About Conjunctivitis Industry The overviews, SWOT analysis and strategies of each vendor in the Conjunctivitis market provide understanding about the market forces and how those can be exploited to create future opportunities. Key Players in this Conjunctivitis market are:– Novartis (CH) Santen Pharmaceutical (JP) Bausch & Lomb (US) Allergan (US) Sun

Life before Vaccines: Growing up in the 1930s and 40s. Category: Features - Berkeley Daily Planet

Medical science has profoundly changed our lives. I am sure that I would not have survived to this old age without antibiotics, advances in epidemiology and surgery. I was a child in the 1930s. We lived in a flat across the street from my grammar school playground and I had friends in the neighborhood. It was a time when parents simply said “Go out and play” and we did. Our games were hopscotch, kick the can, jacks, tag, jump rope, handball and hide and seek. We cruised on roller skates and bikes, and built club houses out of boxes in vacant lots. We were supposed to come home at twilight, before dark. The milkman, bakery truck and iceman delivered to our doors. We felt safe in our neighborhoods. But my parents were fearful of epidemics. At school In first through 8th grades, I had classmates who suffered from scarlet fever, mumps, measles, German measles, chicken pox and whooping cough. I had rubella and had to stay in bed for several days in a darkened room; they thought light bad

Recalls That Should Be on Your Radar-Week of August 25, 2019 - Contagionlive.com

Image
We’ve compiled a list of recalls issued by the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) from this past week: Brutus & Barnaby LLC Issues Recall for Pig Ears Due to Salmonella Risk Brutus & Barnaby of Clearwater, Florida is recalling all size variations of our Pig Ears for Dogs   because it has the potential to be contaminated with  Salmonella .  Salmonella  can affect animals eating the products and there is risk to humans from handling contaminated pet products, especially if they have not thoroughly washed their hands after having contact with the products or any surfaces exposed to these products. Healthy people infected with  Salmonella  should monitor themselves for some or all of the following symptoms: nausea, vomiting, diarrhea or bloody diarrhea, abdominal cramping and fever. Rarely,  Salmonella  can result in more serious ailments, including arterial infections, endocarditis, arthritis, muscle pain, eye irritation, and urinary

All that you need to know about the multiple sclerosis - Thrive Global

Image
Multiple sclerosis, or MS, is a dependable infection that can influence your mind, spinal string, and the optic nerves in your eyes. It further may cause issues related to vision along with balance also muscle control, followed by different voluntary effects. The impacts are regularly extraordinary for everybody who has the malady. A few people have gentle indications and needn’t bother with treatment. Others will experience difficulty getting around and doing day by day undertakings. MS tend to happen when the safe or usual framework is not same as a result of which the greasy material known as  myelin, which usually  folds over the filaments of nerve for securing  them. Due to the absence of  external shell the  nerves can be  harmed. Scar tissue may shape. Causes of Multiple Sclerosis The reason for different sclerosis is obscure. It’s viewed as an immune system infection where the body’s insusceptible framework assaults its very own tissues. On account of MS, this invulnerable

The last thing we need is another Brexit tongue twister - Telegraph.co.uk

Image
P ity the lexicographers, who have truly had their work cut out this week. As if the process of proroguing hadn’t caused so much head scratching as to leave nail marks all but visible on the nation’s skulls, the word itself has had a similar effect, forcing us to verbalise a tongue-twister of a term we didn’t know existed until a few days ago. But the halcyon days of proroguing our understanding of discombobulating parliamentary terminology are done. Between knowing the intricacies of Article 50 and the Withdrawal Agreement, of the backstop and BRINOs and red, white and blue Brexits, post-referendum dithering has mangled political language beyond recognition. Which a cynic might view as a diversion... https://ift.tt/2ZmKeGW

Bacterial Conjunctivitis Treatment Market to Witness Robust Expansion throughout the Forecast 2019 – 2025 with top key players like Bayer, Hoffman-LaRoche, Merck, Novartis, Pfizer, korn - Indian Columnist

“Bacterial Conjunctivitis Treatment Market” Report has been studied and presents an actionable vision to key participants working in it. This Report gives an analysis that global markets will grow at CAGR of +8% from 2019 to 2025. The report provides a basic overview of the industry in the form of definitions, classifications, applications and market chain structure, profits growth in terms of volume with respect to the market. The study delivers information pertaining to the consumption market share across these topographies as well as the market share accrued by each of these regions. Each section of the report reveals critical information about the global Bacterial Conjunctivitis Treatment market that could be used to ensure strong growth in the coming years. Top Key Vendors in Market: Bayer, Hoffman-LaRoche, Merck, Novartis, Pfizer, korn Get Free Sample Copy of this Report @ https://www.a2zmarketresearch.com/sample?reportId=16681                                    The report

Gruesome cat bite infection sends girl, 6, to operating table - Fox News

Middle East chlamydia rates comparable to other regions - Nature Middle East

Bacterial Conjunctivitis Treatment Market to Witness Robust Expansion throughout the Forecast 2019 – 2025 with top key players like Bayer, Hoffman-LaRoche, Merck, Novartis, Pfizer, korn - Indian Columnist

“Bacterial Conjunctivitis Treatment Market” Report has been studied and presents an actionable vision to key participants working in it. This Report gives an analysis that global markets will grow at CAGR of +8% from 2019 to 2025. The report provides a basic overview of the industry in the form of definitions, classifications, applications and market chain structure, profits growth in terms of volume with respect to the market. The study delivers information pertaining to the consumption market share across these topographies as well as the market share accrued by each of these regions. Each section of the report reveals critical information about the global Bacterial Conjunctivitis Treatment market that could be used to ensure strong growth in the coming years. Top Key Vendors in Market: Bayer, Hoffman-LaRoche, Merck, Novartis, Pfizer, korn Get Free Sample Copy of this Report @ https://www.a2zmarketresearch.com/sample?reportId=16681                                    The report

Hurricane Dorian: AdventHealth to offer free telemedicine starting Monday - Orlando Sentinel

Image
Due to Hurricane Dorian, the Orlando VA Healthcare System is cancelling all scheduled appointments for Tuesday, Sept. 3, at its outpatient clinics in Viera, Daytona Beach, Lake Baldwin, Lake Nona, Deltona, Clermont, Tavares, and Kissimmee. For more information, click here . https://ift.tt/34fVhAr

Hurricane Dorian: AdventHealth to offer free telemedicine starting Monday - Orlando Sentinel

Image
Due to Hurricane Dorian, the Orlando VA Healthcare System is cancelling all scheduled appointments for Tuesday, Sept. 3, at its outpatient clinics in Viera, Daytona Beach, Lake Baldwin, Lake Nona, Deltona, Clermont, Tavares, and Kissimmee. For more information, click here . https://ift.tt/34fVhAr

The Truth Behind What's Actually Living On Our Favourite Statues… - Yahoo Finance

Signs and symptoms of pink eye (and when to be concerned) - Fox Baltimore

Global Conjunctivitis Therapeutics Market Analyzed With Trends And Opportunities By 2024 - Business Intelligence

Image
The Conjunctivitis Therapeutics market was valued at XX Million US$ in 2018 and is projected to reach XX Million US$ by 2024, at a CAGR of XX% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2024 as the forecast period to estimate the market size for Conjunctivitis Therapeutics. Global Conjunctivitis Therapeutics industry market professional research 2014-2024, is a report which provides the details about industry overview, industry chain, market size (sales, revenue, and growth rate), gross margin, major manufacturers, development trends and forecast. To access the sample report of the Conjunctivitis Therapeutics market visit at: https://www.orbisresearch.com/contacts/request-sample/3611671 Key players in global Conjunctivitis Therapeutics market include: Akorn, Incorporated ALLERGAN Bausch Health Novartis AG Santen Pharmaceutical Market segmentation, by product types: Allergic conjunctivitis Bacterial conjunctivitis Viral

Bacterial Conjunctivitis Drugs Market Size, Growth Trends, Top Players, Applicat - ITResearchBrief.com

Image
The ' Bacterial Conjunctivitis Drugs market' study Added by Market Study Report, LLC, delivers an in-depth outline regarding the powerful trends existing within the industry. The study also comprises significant information concerning growth prospects, growth dynamics, market share, market size and revenue estimation of this business vertical. The report further features highlight key challenges and growth opportunities faced by the contenders of this industry, as well as enlightens the current competitive setting and growth plans enforced by the Bacterial Conjunctivitis Drugs market players. A detailed analysis of the Bacterial Conjunctivitis Drugs market has been compiled in this research study, inclusive of prominent factors such as the market size with respect to volume and remuneration. Also, the study elucidates in extensive detail the generic industry segmentation as well as a reliable evaluation of the current status of the Bacterial Conjunctivitis Drugs market. The

Global Acute and Chronic Allergic Conjunctivitis Treatment Market 2019 -2024 By To Manufactures Profile, User-Demand, SWOT Analysis, Cost Structure & Revenue - Business Intelligence

Image
The Acute and Chronic Allergic Conjunctivitis Treatment market was valued at XX Million US$ in 2018 and is projected to reach XX Million US$ by 2024, at a CAGR of XX% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2024 as the forecast period to estimate the market size for Acute and Chronic Allergic Conjunctivitis Treatment. Global Acute and Chronic Allergic Conjunctivitis Treatment industry market professional research 2014-2024, is a report which provides the details about industry overview, industry chain, market size (sales, revenue, and growth rate), gross margin, major manufacturers, development trends and forecast. To access the sample report of the Acute and Chronic Allergic Conjunctivitis Treatment market visit at: https://www.orbisresearch.com/contacts/request-sample/3611675 Key players in global Acute and Chronic Allergic Conjunctivitis Treatment market include: Akorn, Incorporated ALLERGAN Bausch Health Novartis AG

Signs and symptoms of pink eye (and when to be concerned) - Fox Baltimore

Posture-based change in IOP found in glaucoma patients - Healio

Image
Changes in IOP resulting from posture shifts were comparable among various forms of glaucoma, according to findings published in Optometry Vision and Science . Ji-Hye Park, MD, PhD, and colleagues investigated the effects of different body postures on the IOP in eyes suspected of having primary angle-closure and those with primary angle closure or primary angle-closure glaucoma. “Elevated IOP is a key modifiable risk factor for the development or progression of glaucoma,” Park, of the department of ophthalmology at Korea University, and colleagues wrote. “Therefore, IOP measurement constitutes a major component of routine examinations performed in diagnosing or managing glaucoma.” Park and colleagues measured IOP using Tonopen Avia (Reichert) in sitting, supine and right and left lateral decubitus positions. The main outcome was the difference in IOP among different body postures. The researchers evaluated the eyes of 31 patients (N = 62 eyes; mean age, 63 years; 83% women) and

VIDEO: Mnemonic helps ensure ocular surface integrity in glaucoma patients - Healio

Image
Loading... Healio Ophthalmology Glaucoma Meeting News Video Women in Ophthalmology Summer Symposium August 30, 2019 COEUR D’ALENE, Idaho — At the Women in Ophthalmology Summer Symposium, Lisa M. Nijm , MD, JD, discusses her presentation on minimizing the effects of glaucoma treatment on the ocular surface. COEUR D’ALENE, Idaho — At the Women in Ophthalmology Summer Symposium, Lisa M. Nijm , MD, JD, discusses her presentation on minimizing the effects of glaucoma treatment on the ocular surface. See more from Women in Ophthalmology Summer Symposium '); if (initPager()) { paramarray = window.location.search.substr(1).split('&'); paramarray.forEach(function (p) { kvp = p.split('='); if (kvp.length != 2) return false; if (kvp[0].toLowerCase() == 'page') page = (kvp[1] - 1); }); page = (page + 1) > pages.length || !$j.isNumeric(page) ? 0 : page; setPage(page); } medrect1 = $j("[data-module='AD Medium Rectangle 1'

Netarsudil lowers IOP in glaucoma, ocular hypertension - Medical Xpress

'Silent thief of sight': Millions have glaucoma, half don't know they have it - WSOC Charlotte

Image
CHARLOTTE, N.C. - Three million Americans have glaucoma, an eye condition that causes a slow loss of vision, but half do not even know they have it.  Glaucoma is often called the "silent thief of sight" because people will not notice symptoms until the condition is moderate or advanced. It can be slowed or prevented, but there is no cure.  [ALSO READ: Why are more children being diagnosed as nearsighted?] "You probably take your eyesight for granted, but it can be taken away from you," Calvin Blanton said.  This is a personal issue for Eyewitness News Anchor Scott Wickersham, who was diagnosed with glaucoma. Now, he is dedicated to spreading awareness.  Thursday at 5:15 p.m. on Channel 9, Scott investigates who is most at risk and what you need to know.  © 2019 Cox Media Group. https://ift.tt/2zzEj28

MIGS Devices Continue to Expand Use of Glaucoma Surgery - PRNewswire

Image
Market Scope examines this shifting landscape in its newly published "2019 Glaucoma Surgical Device Market Report." Glaucoma is the world's second leading cause of blindness. The disease affects nearly 100 million people around the globe, according to Market Scope estimates. Another 41 million have ocular hypertension, a condition that often precedes glaucoma. There are four FDA-approved MIGS stents in the US: the Glaukos iStent and iStent inject, Allergan XEN gel stent, and Ivantis Hydrus. The number of participants will grow soon with the expected approval of the Santen PreserFlo Microshunt. Medication is the most frequently prescribed treatment for mild to moderate stages of glaucoma. Surgery typically is chosen only when medications are no longer able to control the disease. Only 2.0 percent of diagnosed glaucoma patients globally were treated surgically in 2018. Laser treatments are the most frequently chosen option to treat glaucoma patients who are no longer re

Study Shows MIGS Makes up Nearly Half of Glaucoma Surgical Device Revenue - Medical Device and Diagnostics Industry

Image
Micro-invasive glaucoma surgery (MIGS) stents are quickly becoming the norm. A new study from Market Scope titled “2019 Glaucoma Surgical Device Market Report,” shows that MIGS stents account for almost half of all glaucoma surgical device revenue in 2019. This is an even more impressive feat for the devices considering the loss of revenue that occurred from the Cypass Micro-Stent being recalled nearly a year ago . Alcon pulled Cypass off the market after five-year data revealed a higher rate of cell loss compared to patients who had cataract surgery alone. However, the report said Cypass being pulled off the market did slow down the adoption of MIGS devices and opened the door for other surgical and laser treatments. There are four FDA-approved MIGS stents: the Glaukos’s iStent and iStent inject, Allergan XEN gel stent, and Ivantis Hydrus. That number could grow as Santen Pharmaceutical’s PreserFlow MicroShunt is the next MIGS device in line for FDA approval, the report said. Ear

DE-128 microshunt reduced IOP, medications in study - Healio

Image
A multicenter study found the DE-128 microshunt implanted intraoperatively with 0.2 mg/mL concentration of mitomycin C effectively reduced IOP in patients with primary open-angle glaucoma not controlled with maximum tolerated glaucoma medications, Santen Pharmaceutical announced in a press release. The INN-005 prospective, randomized, controlled, single-masked study compared patients who received DE-128 implanted intraoperatively with 0.2 mg/mL concentration of MMC against the standard of care of trabeculectomy with the same concentration of MMC. Patients implanted with DE-128 experienced a mean diurnal IOP reduction from 21.1 ± 4.9 mm Hg to 14.2 ± 4.4 mm Hg at month 12 compared with a reduction from 21.1 ± 5 mm Hg to 11.2 ± 4.2 mm Hg in the trabeculectomy group, according to the release. The mean number of glaucoma medications decreased in both groups, from an average of three medications at screening to 0.6 in the DE-128 group and 0.3 in the trabeculectomy group. At month 12, 71.

Signs and symptoms of pink eye (and when to be concerned) - Fox Baltimore

You Have 14 New Netflix Treats To Binge This Labor Day Weekend — Here's What's Worth Watching - Refinery29

Image
While the company is touting its sci-fi puppet series The Dark Crystal: Age of Resistance , premiering today, August 30, it's not the only Netflix treat you’ll find competing for your eyeballs. Over the last week, the service has also debuted glam Queer Eye soul sibling Styling Hollywood , a brand new cache of foreign-language fare , and the most promising pick of the bunch, The A List . The latter new series — a mix of The Society , Lost , and the Midsommar costume department — may be headed for viral teen show greatness. https://ift.tt/2L7ckxb

Beset by lawsuits and criticism in U.S., opioid makers eye new market in India - FiercePharma

Signs and symptoms of pink eye (and when to be concerned) - Fox Baltimore

Avera Medical Minute: Eye exams benefit kids going back to school - KSFY

Image
Getting kids off to a good start for the school year often includes getting school supplies and some new clothes. There is one thing that could be overlooked, your children's eye exam. Jack Weber and his sister Brylee are coming in for an eye exam. Jack says his eyesight is great. "Carrots help you get good eyesight," says Jack. If he were outside, Jack says he could see for fifty miles. Older sister Brylee Weber remembers what it was like last year. "I looked at a bunch of charts a lot. He put lights, He used lights and looked at my eyes," said Brylee. Being a Cheerleader, she says having good vision is crucial."Very important," said Brylee. "You don't want to kick anyone or have anyone coming on to you." If an eye doctor can make an eye exam fun, Avera Orthoptist Joey Martin can. He specializes in kid's vision and pediatric vision disorders and says several signs could be indicators that vision correction is needed. "Ofte

John Moses: Family of five booted to the street - Charleston Gazette-Mail

Image
It was on a Monday late morning in October that I met Cassie. She wheeled a stroller into my office with two toddlers in tow. She had just given birth to daughter number three. Her smile faded quickly when she told me she had to appear that afternoon for an eviction hearing. She was in arrears with the rent to the tune of $750, reflecting one and a half months. She explained she and her husband were both working until two months before her delivery. Complications with her pregnancy resulted in her doctor ordering bed rest. Soon after, her husband’s work hours were reduced. He is a midlevel manager in a fast-food restaurant. After several weeks he was about to have his hours reinstated, but his children contracted pink eye and he wasn’t permitted to return until they were well. Could I help, she asked? I offered to write her a letter she could present to the court requesting 30 days to give me time to contact her landlord, and hopefully reverse this eviction and resolve her sit

MIGS Devices Continue to Expand Use of Glaucoma Surgery - BioSpace

Image
ST. LOUIS , Aug. 29, 2019 /PRNewswire/ -- Minimally invasive glaucoma surgery (MIGS) stents account for nearly half of all glaucoma surgical device revenue in 2019. Market penetration of these stents over the past five years has been impressive, but the voluntary recall of the Alcon CyPass in 2018 slowed the adoption rate. It also opened the door for other surgical and laser treatments. Market Scope examines this shifting landscape in its newly published "2019 Glaucoma Surgical Device Market Report." Glaucoma is the world's second leading cause of blindness. The disease affects nearly 100 million people around the globe, according to Market Scope estimates. Another 41 million have ocular hypertension, a condition that often precedes glaucoma. There are four FDA-approved MIGS stents in the US: the Glaukos iStent and iStent inject, Allergan XEN gel stent, and Ivantis Hydrus. The number of participants will grow soon with the expected approval of the Santen PreserFlo

Most intriguing 2019 NFL season-long player prop bets - Yardbarker

Image
Ryan Fowler runs down what he believes are the most intriguing NFL player prop bets this season.   Brian Spurlock-USA TODAY Sports It'll go down as one of those classic "where were you when" moments, and you'll remember. Andrew Luck's shocking retirement announcement shook not only the NFL but also sportsbooks around the world. In the blink of an eye, the Indianapolis Colts ' Super Bowl odds cratered from 16-to-1 to 50-to-1. However, some believe Luck's departure is only temporary and that once his body fully heals, he'll miss the bright lights and return to the field. In fact, Bovada posted these future odds about Luck earlier this week: Where will Andrew Luck play in 2020 or 2021? NFL (+500) | XFL (+1,500) | neither league (-4,000) So if you don't believe Luck will play professional football and he doesn't return before the end of the 2021 season, you'd have to wager $4,000 to have a shot at $100 in return. What's more f